Pier Capital LLC Acquires 85,849 Shares of Certara, Inc. $CERT

Pier Capital LLC boosted its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 11.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 840,449 shares of the company’s stock after purchasing an additional 85,849 shares during the quarter. Pier Capital LLC owned about 0.53% of Certara worth $7,404,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Horizon Corp bought a new stake in Certara during the 3rd quarter valued at approximately $30,000. Versant Capital Management Inc raised its stake in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. raised its stake in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Global Retirement Partners LLC raised its stake in Certara by 45.0% during the 3rd quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock valued at $69,000 after purchasing an additional 1,749 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the period. Institutional investors own 73.96% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on CERT shares. Leerink Partners reissued an “outperform” rating and set a $10.00 target price on shares of Certara in a research note on Thursday, February 26th. KeyCorp decreased their target price on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective on the stock. in a research note on Friday, February 27th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $8.00 price objective on shares of Certara in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara presently has an average rating of “Moderate Buy” and a consensus target price of $10.44.

Certara Stock Performance

NASDAQ:CERT opened at $6.31 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. Certara, Inc. has a 1 year low of $5.19 and a 1 year high of $13.88. The stock’s 50 day simple moving average is $6.25 and its two-hundred day simple moving average is $8.11. The company has a market cap of $967.45 million, a price-to-earnings ratio of -631.00 and a beta of 1.53.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million during the quarter, compared to the consensus estimate of $103.23 million. During the same period in the previous year, the firm earned $0.15 EPS. The business’s revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts anticipate that Certara, Inc. will post 0.29 earnings per share for the current fiscal year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.